NPS Pharmaceuticals Earnings Conference Call (Q2 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Aug 6 Calls Today's Calls

Call Details NPS Pharmaceuticals Earnings Conference Call (Q2 2009) Thu, Aug 6, 2009, 9:00 am Eastern Listen to the archived event audio About NPS Pharmaceuticals (NasdaqGM:NPSP) NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of specialty therapeutics for gastrointestinal and endocrine disorders. The company is advancing two late-stage programs to restore or replace biological function, including GATTEX (teduglutide), which is in Phase 3 clinical development for parenteral dependent short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) that is in Phase 3 clinical development as a hormone therapy for hypoparathyroidism. It complements its internal programs with strategic partnerships with Amgen, GlaxoSmithKline, Kyowa Kirin, and Nycomed. The company was founded in 1986 and is headquartered in Bedminster, New Jersey. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings